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Abstract
Purpose Gastro-oesophageal reflux disease (GORD) is commonly thought to play an important role in chronic cough and 
patients are often empirically treated with acid suppression therapy. We sought to investigate the response rate to acid sup-
pression treatment in patients with and without heartburn attending two specialist cough clinics.
Methods A retrospective review of 558 consecutive patients referred to two specialist cough clinics was performed (UK 
and USA). Patients who were treated with acid suppression were included and their documented response to treatment was 
collected. Binary logistic regression was used to ascertain the value of reported heartburn in predicting the response of 
chronic cough to acid suppression therapy.
Results Of 558 consecutive referrals, 238 patients were excluded due to missing data or cough duration of < 8 weeks. The 
remaining 320 patients were predominantly female (76%), with mean age 61 yrs (± 13) and 96.8% non-smokers, with chronic 
cough for 36 (18–117) months. Of 72 patients with heartburn, 20 (28%) noted improvement in their cough with acid suppres-
sion, whereas of 248 without heartburn, only 35 (14%) responded. Patients reporting heartburn were 2.7 (95% C.I. 1.3–5.6) 
times more likely to respond to acid suppression therapy (p = 0.007).
Conclusion In specialist cough clinics, few patients report a response of their chronic cough to acid suppression therapy. 
Nonetheless, heartburn is a useful predictor substantially increasing the likelihood of benefit.
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Introduction
Gastro-oesophageal reflux disease (GORD) is thought to 
play an important role in chronic cough [1–3]. Some stud-
ies estimate between 10% and 40% of chronic cough is 
related to GORD [4, 5]. Various mechanisms linking reflux 
and cough have been suggested, such as micro-aspiration 
of gastric content and/or stimulation of a vagal oesophago-
bronchial reflex. [6, 7]. Validated measures demonstrating 
reflux reach the larynx/pharynx or biomarkers of micro-
aspiration are lacking, making proximal reflux and micro-
aspiration difficult to evaluate. However, several lines of 
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evidence support the concept of reflux evoking cough via 
a vagal reflex, for example, Smith et al. 2010 have shown 
that in 48% of unselected chronic cough patients there 
were temporal associations between reflux and cough [5]. 
Interestingly, abnormalities of oesophageal motility asso-
ciated with chronic cough demonstrate slow clearance of 
both swallowed food and refluxate. The longer residence of 
such material in the oesophagus may enhance stimulation 
of vagal reflexes [4].
The cost of treating atypical GORD symptoms, such 
as cough, with acid suppressants far outweighs the cost 
of treating typical GORD symptoms with studies quoting 
a 5.6 × greater cost [10]. Thus being able to select which 
chronic cough patients are more likely to respond to acid 
suppression is vital, in order to prevent excessive waste 
of resources and unnecessary risks associated with pro-
longed drug treatment for the patient. Treatment trials of 
acid suppressing therapy (proton pump inhibitors (PPIs), 
H2 antagonists ± alginates) used to be recommended as 
part of all guidelines for the management of patients with 
chronic cough [3]. Recent guidelines only recommend 
trials of acid-suppressant therapy in those with evidence 
of pathological reflux or heartburn. This is based on a 
retrospective analysis of pooled data from 9 randomised 
trials in patients thought to have extra-oesophageal symp-
toms of reflux, of which chronic cough was a subgroup [8]. 
This study suggested that therapeutic gain is most likely 
to be seen in those with abnormal 24-h pH monitoring or 
reported heartburn. These studies were all small (the larg-
est was n = 39 patients) and therefore the total number of 
subjects in this analysis was only 163 and the predictive 
value of reflux symptoms and measures was not clear.
We set out to investigate the real-world response rate 
of acid suppression treatment in patients attending two 
specialist cough clinics and in particular which factors 
predicted likelihood of success of treatment.
Materials and Methods
Participants
Patients who had a cough persisting longer than 8 weeks, 
with documented evidence of treatment with antacid sup-
pression therapy and no significant lung pathology were 
included. The response to treatment recorded in the notes 
was collected. As the degree of treatment response was not 
documented in a standard format, patients were catego-
rised as responders if any improvement was documented. 
Any patients with missing duration of cough or response 
to treatment were excluded.
Study Design
A retrospective review of the case notes of chronic cough 
patients attending two specialist cough services was con-
ducted; one from the UK specialist tertiary clinic (Wythen-
shawe Hospital, Manchester University Foundation Trust, 
Manchester, UK) and the other from the US clinic (Mayo 
clinic, Jacksonville, Florida, USA) over a 12-month period 
from October 2013 to October 2014. Both clinics worked to 
very similar management protocols and based on the guide-
lines at the time, all patients received a trial of acid suppressing 
therapy.
Patients attending the Manchester clinic were referred from 
secondary care clinicians, whereas patients attending the US 
clinic could self-refer and were often referred directly from 
their primary care provider. As this was a review of clinical 
notes and the data were collected as part of routine care, no 
formal ethics approval was sought, but this review was regis-
tered with the local clinical audit and governance department. 
The Mayo clinic study required ethical approval and this was 
obtained (IRB 15-002903).
Data Collection
Clinic proformas which captured data on age, sex, cough dura-
tion, lung function, treatment trials, and additional symptoms 
(such as heartburn) were used. Both groups of patients under-
went history and examination by a physician. Routine investi-
gations (radiology, full lung function tests, bronchial provoca-
tion tests, and bronchoscopy) were then carried out to exclude 
any significant causes of cough. Patients who had a persistent 
cough of greater than 8-week duration were included. The US 
clinic patients were seen by ear, nose, and throat specialists, 
pulmonology, and gastroenterologist, whereas the UK group 
were seen by pulmonology only. As part of their routine care, 
all patients then completed a treatment trial of dual acid sup-
pression therapy (if not treated previously). This consisted 
of dual antacids in the form of PPIs (e.g. Omeprazole 20 mg 
BD/Lansoprazole 15 mg BD) plus a H2 antagonist (Raniti-
dine 300 mg OD) for a minimum of 8 weeks. The addition of 
nocturnal H2 antagonist to the dual PPI regimen is in order 
to enhance nocturnal gastric pH control and decrease noctur-
nal gastric acid breakthrough [9, 10] thus reducing the likeli-
hood of reflux cough being triggered. Response of cough to 
acid suppression therapy was based on patient reported and 
physician judgement documented as yes/no response in the 
proforma.
Statistical Analysis
The data were analysed using IBM SPSS version 22, 2013. 
Data were summarised as mean/median depending on the 
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distribution. Mann–Whitney test was used to generate p 
value for non-normally distributed non-parametric data. 
Independent sample T test was used for the normally dis-
tributed data. Binary logistic regression was used to model 




Information was collected on 558, of those 238 patients were 
excluded (20 UK and 218 US). The reasons for exclusion 
were as follows: (i) the duration of cough not being docu-
mented, (ii) response to acid suppression not documented, 
and (iii) presence of heartburn not documented and patients 
not having chronic cough for > 8 weeks. Three hundred 
and twenty patients were included in final dataset (Fig. 1). 
Comparison of the two clinics indicated that there were 
some statistically significant differences between patients 
attending the UK clinic and the US clinic (Table 1). The US 
cohort was slightly older (64 ± 13 vs 57 ± 11.3 years), with 
a shorter duration of cough (30 vs 48 months) and reported 
less heartburn (16% vs 32.8%). The majority of patients 
were female (71%) and the mean age was 61 ± 13 years 






218 excluded (213 antacid 
response/treatment not 
documented, 5 cough 













20 excluded due to antacid 
response/treatment not 
documented  n= 116 
Fig. 1  Summary of patient data analysed
Table 1  Patient characteristics across both clinics
Statistically significant P values are given in bold
* Mean (SD) 
** Median (IQR)
UK (n = 116) US (n = 204) P
Age (years)* 57 ± 11.3 64 ± 13.0  <0.001
Sex Female (%) 84 (72) 143(70) 0.756
Cough duration (months)** 48 (24–120) 30 (12–96)  <0.001
Smoking history 0.72
Current 2 (1.7) 6 (3)
Ex-smokers 31 (26.7) 75 (37)
Never smokers 81 (69.8) 123 (60)
Missing data 2 0










Heartburn 38 (32.8%) 34 (16%) 0.002
Acid suppression response 15 (12.9%) 40 (20%) 0.171
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Responders and non-responders of cough to acid suppres-
sion were well matched, with no significant differences in 
lung function (FEV1 and FVC), smoking status, sex, and 
age (Table 1).
Heartburn Symptoms and Acid Suppression 
Response
Only 72 (23%) patients reported heartburn and of these 
only 20 (28%) reported an improvement in cough. Of the 
248 patients reporting no heartburn, 35 (14%) reported an 
improvement in cough in response to acid suppressing ther-
apy. In the pooled cohort, only 17% (55/320) of all patients 
reported a response of their cough to acid suppression ther-
apy (Fig. 1). There was no significant difference between 
patients from the two different clinics in terms of likelihood 
of success of acid suppression therapy. A chi-squared test 
showed that the presence of heartburn was significantly 
higher in responders than in non-responders (p = 0.007). The 
sensitivity of heartburn as a symptom in detecting response 
of cough to acid suppression was 36.4% and the specificity 
was 80.4%.
Binary logistic regression was carried out to ascertain the 
value of heartburn for predicting the likelihood of a response 
to acid suppression (Table 2). The model indicated that the 
presence of heartburn significantly predicted success of 
acid suppression therapy, p = 0.007. Furthermore, patients 
reporting heartburn were 2.7 times (95% C.I. 1.3–5.6) more 
likely to have a response of their cough to acid suppression 
therapy. A multivariate analysis of variables, such as age, 
sex, and lung function, did not have any significant effect 
on the likelihood of success of acid suppression, nor did the 
clinic site.
Discussion
To our knowledge, this is the largest study of the effect of 
acid suppression on cough in patients with chronic cough. 
Our findings indicate that heartburn is the only significant 
predictor of success of acid suppression therapy when treat-
ing chronic cough in a ‘real-life’ setting. However, it must 
be acknowledged that only just over a third of those with 
heartburn gained benefit. [8, 10, 11].
Evidence that acid suppression improves cough in chronic 
cough patients is limited to studies with a small number of 
patients. Kahrilas et al. carried out a retrospective review 
and found nine RCTs on the effect of acid-suppressive ther-
apy (either PPIs or the H2 antagonist ranitidine) on chronic 
cough symptoms [8]. Six of these studies did not report a 
significant improvement in cough, but two of these nega-
tive studies excluded patients with heartburn [11, 12]. It is 
also worth noting that the 3 of the negative studies included 
patients without pathological evidence of oesophageal acid 
exposure. Kahrilas et al. report that the therapeutic gain of 
treating chronic cough patients with acid-suppressive treat-
ment was low and variable (between 8.6% and 35.8%) but 
is increased by selecting patients who report heartburn as a 
symptom. This is in keeping with the findings of our larger 
study. A more recent study of 312 patients with acute and 
sub-acute cough found that 46% had GORD symptoms, such 
as heartburn, which are significantly higher than in our study 
[13]. However, this may be due to the inclusion of a popula-
tion with shorter duration of cough. The same group went 
Table 2  Patient characteristics
Statistically significant P values are given in bold
Values are expressed as the mean ± SD for normally distributed continuous variables*, the median (IQR) 
for non-normally distributed data**, and frequency (percentage) for discrete variables. Chi-squared test 
was performed for parametric data. Significance: P ≤ 0.05. Mann –Whitney U test for non-parametric data. 
Significance: P ≤ 0.05
All patients (n = 320) Responders (n = 55) Non-responders 
(n = 265)
p
Age (years)* 61 ± 13 64 ± 14 61 ± 13 0.064
Female, n (%) 227(71) 35 (64) 192 (72) 0.126
FEV1 (percent predicted)* 88 (21) 86 (22) 88 (21) 0.494
FVC (percent predicted)* 94 (19) 92 (19) 95 (19) 0.343
Cough duration** (months) 36 (18–117) 36 (12–120) 36(18–96) 0.413
Heartburn n (%) 72 (23) 20 (36%) 52 (20%) 0.007
Smoking status 0.293
Never 204 (63.7) 38 (69.1) 166 (62.9)
Ex 106 (33.1) 15 (27.3) 91 (34.3)
Current 8 (2.5) 1 (1.8) 7 (2.6)
Missing data 2 1 1
601Lung (2021) 199:597–602 
1 3
on to investigate the effects of acid suppression treatment 
in patients with chronic cough in a smaller study (n = 37), 
selecting patients with both heartburn and cough and treat-
ing them with a PPI and prokinetic agent. Again, patients 
with GERD symptoms and cough improved significantly 
with acid suppression, consistent with our findings.
The most important finding of this study is the low 
response rate of chronic cough to acid suppression, even in 
the context of heartburn. Only 17% of the patients in this 
dataset reported a response of their cough to acid suppres-
sion which reflects the treatment refractory nature of chronic 
cough patients seen in specialist clinics [14]. Despite this 
low response rate, heartburn was a highly significant predic-
tor of the likelihood of success of acid suppression therapy 
(p = 0.007) and resulted in a near threefold increase in the 
success of treatment. It is worth noting, however, that the 
vast proportion of patients with chronic cough with con-
comitant heartburn that responds to acid suppression are 
probably managed in the community and thus are far less 
likely to present to specialist clinics. A large epidemiological 
study looking at 14,669 individuals in a population-based 
cohort found that reported gastro-oesophageal reflux disease 
was a significant risk factor for chronic cough, especially in 
never and former smokers [17]. Another possible explana-
tion for the low numbers of responders to acid suppression 
is that these therapies only suppress the acidity of the reflux-
ate and have no effect on non-acid reflux or the number of 
reflux events. Decalmer et al. 2010 found that approximately 
2/3 of reflux events in chronic cough patients were non-acid 
[5]. Other studies also report that chronic cough patients 
have an increased incidence of weak peristalsis with large 
breaks leading to poor oesophageal clearance of reflux [4, 5]. 
Thus, acid suppression alone may be ineffective at treating 
the commonest types of reflux in this patient group. In order 
to explore this further trials in chronic cough patients using 
therapies that target lower oesophageal sphincter relaxations, 
reducing non-acid and acid reflux and/or poor oesophageal 
clearance are needed.
Our dataset was typical of patients attending specialists 
cough clinics with the majority of patients being females 
between the ages of 50–60 years old, with normal spirome-
try and non-smokers. The patients in the responder vs non-
responder group were well matched, with no significant 
differences between them (apart from reporting of heart-
burn). There were some statistically significant differences 
between the patients attending the US clinic and those 
attending the UK one (Table 2). The US group was older, 
had a lower FVC, and reported shorter duration of their 
cough than the UK group. However, none of these differ-
ences impacted our results. Although the US group was 
older they are still within the typical age group of chronic 
cough patients [14, 15]. The US clinic was based in Flor-
ida which is a popular retirement destination, and although 
we do not have data on where the patients attending the 
clinic came from, we speculate that the increased age may 
simply reflect the local population. The FVC percent pre-
dicted was slightly lower in the US patients; however, this 
did not reflect a clinically relevant difference. It is possible 
that there was a difference in body mass index between 
the patients attending the two clinics that can account for 
the difference in FVC; however, we do not have data on 
BMI for the UK patients. Subjects in the US group had 
a shorter duration of cough, but this is not clinically sig-
nificant as these patients would still be classed as chronic 
cough patients. Furthermore, the duration of cough was 
not a significant factor between the responders and non-
responders. One explanation for the difference in cough 
duration is that the US clinic accepts direct GP/primary 
care/self-referrals, whereas the UK clinic only accepts 
patients from secondary care. Thus, there is a delay from 
presentation to specialist clinic review (in the UK) which 
might account for the difference in cough duration. Twice 
as many patients in the UK group complained of heartburn 
compared to the US group (32.8% vs. 16%), although on 
the whole the numbers were small in both groups. The 
wider availability of over-the-counter acid suppression 
medication in the US and therefore the possibility of self-
management of reflux compared to the UK could account 
this difference with patients successfully treating acid 
reflux-related chronic cough and avoiding the need for 
referral to specialist clinics. In general, UK patients need 
to be seen by a doctor prior to being prescribed acid sup-
pression (at least for significant periods and at treatment 
doses), whereas in the US patients self-medication with 
these drugs is common, with treatment level doses being 
readily available over the counter. Despite the difference 
in the number of patients with heartburn in each group, 
this did not translate to a significant difference in the PPI 
response rate when the data were modelled.
At the time of collecting the data for this study, guidelines 
recommended treatment trials of acid suppression therapy 
as routine for all patients with chronic cough even in the 
absence of GORD symptoms, such as heartburn [16]. Our 
study data do not support this practice and suggested that 
acid suppression is unlikely to be successful in the major-
ity of patients with chronic cough, which led to a change in 
practice in our centre. Since then, the guidelines have been 
updated and now discouraged routine empirical acid sup-
pression use in these patients [17, 18].
Due to the observational and retrospective nature of this 
study the findings should be interpreted with some caution. 
As with all observational studies, misclassification of data or 
information bias when collecting the data may have occurred. 
Patients with incomplete or missing information on duration 
of cough, heartburn symptoms or duration of antacid therapy 
were excluded. The dosage of acid suppression therapy used 
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was at the discretion of the prescribing clinician. However, 
both centres followed the current chronic cough guidelines 
[19, 20] on the management of GORD-related cough. Thus, 
although the dosing regimen may have differed between 
patients the treatment was in line with current guidelines and 
reflective of what happens in a real-life setting.
As this was a retrospective review, there were no validated 
endpoints. We used the reporting of heartburn and cough 
response as the main variables, which were both subjectively 
measured. There was no formal standardised way of measur-
ing heartburn and thus this could vary between patients and 
clinicians and the degree of response was not recorded in a 
standard manner and therefore cannot be reported.
Conclusion
This study suggests that heartburn is a predictor of the like-
lihood of chronic cough responding to acid suppression. 
Although this is consistent with previous retrospective anal-
ysis of clinical trial data, our analysis reveals that the overall 
proportion of patients with chronic cough responding acid 
suppression is low in a specialist cough setting. The majority 
of these patients’ cough was resistant to therapy.
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